170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors
Title:
170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors
Author:
Jeger, S. Schönborn-Kellenberger, O. De Winter, H. Steeghs, N. Gort, E. Gomez-Roca, C. Stavropoulou, V. Kenefeck, R. Fernandez, E. Ji, H. Marchand, C. Legenne, P. Cassier, P.